

AroCell's Tumor Marker TPS to be introduced on a leading Japanese IVD company's new Automated CLIA Platforms in China

AroCell has through its partner, ZECEN, established a new strategic partnership with a leading global Japanese IVD company, significantly enhancing their market presence in China by incorporating TPS CLIA on their automated CLIA platforms.

ZECEN has initiated a collaboration with a major publicly traded Japanese IVD company with presence in over 190 countries, to integrate various markers, including AroCell's TPS, on their automated CLIA platforms in China. Currently, TPS CLIA is integrated into ZECEN Biotech and Fosun Diagnostics' automated CLIA platforms within the Chinese market. The Japanese company has over 2 500 CLIA platforms installed in China, and TPS CLIA will gradually be implemented on these platforms. In the future, all new automated CLIA platforms will be delivered with TPS CLIA as part of their panel of tumor markers.

"This new collaboration, combined with advancements in our other projects, marks significant milestones in our strategy to enhance our presence in the Chinese market. We anticipate that these initiatives will drive our long-term growth and success. By integrating our tumor markers onto additional CLIA platforms, we are enhancing our ability to provide superior solutions to our customers. This will result in faster and more reliable diagnoses, thereby improving patient care and facilitating more effective treatments", says Anders Hultman, CEO of AroCell.

As part of the collaboration, an initial order of TPS tests will be placed in the beginning of next year. This represents a significant milestone for AroCell, as it not only enhances our market presence in China but also facilitates the wider clinical application of our TPS product across more hospitals than previously.

AroCell has several ongoing development projects with ZECEN. The UBC CLIA project is nearing a critical transition from the development phase to the validation phase. Concurrently, the development of the TK1 CLIA project is also progressing well. Both products are planned for registration submission to NMPA by the end of 2025.

Automated CLIA platforms are advanced diagnostic systems used to perform chemiluminescent immunoassays (CLIA). These systems manage the entire analysis process—from sample preparation to the reporting of results—eliminating the need for manual intervention. This automation ensures high precision and reliability in assay outcomes while also facilitating an efficient workflow that can accommodate large volumes of samples continuously.

Contacts

Anders Hultman, CEO
Phone: +46 (0) 8 799 67 50
E-mail: anders.hultman@arocell.com

About AroCell

AroCell AB (publ) is a Swedish company that develops and markets blood and urine sample tests. The corporation specializes in oncology and bacteriology. The company has a broad product portfolio, used in healthcare, and established in various markets. In oncology, AroCell uses various biomarkers, TK1, and cytokeratins, to support the treatment of various cancers such as breast, prostate, and bladder cancers. AroCell's product portfolio also includes a rapid bacteriological test for a simple and safe diagnosis of typhoid fever. AroCell (AROC) is listed on Nasdaq First North Growth Market with Redeye AB as company's Certified Adviser. For more information; www.arocell.com

This information is information that AroCell is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-12-17 11:39 CET.

Attachments

[AroCell's Tumor Marker TPS to be introduced on a leading Japanese IVD company's new Automated CLIA Platforms in China](#)